- Xenon Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
- Xenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual Meeting
- Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Xenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2024
- Xenon Pharmaceuticals to Present at the 2024 RBC Capital Markets Global Healthcare Conference
- Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Corporate Update
- Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting
- Xenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
- Xenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference
- Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days
More ▼
Key statistics
On Wednesday, Xenon Pharmaceuticals Inc (XENE:NMQ) closed at 36.12, 29.07% above the 52 week low of 27.99 set on Nov 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 36.64 |
---|---|
High | 37.01 |
Low | 35.73 |
Bid | 36.12 |
Offer | 38.01 |
Previous close | 36.56 |
Average volume | 517.37k |
---|---|
Shares outstanding | 75.47m |
Free float | 74.29m |
P/E (TTM) | -- |
Market cap | 2.76bn USD |
EPS (TTM) | -2.71 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 18:00 BST.
More ▼